Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.

PFS was longer with nivolumab plus ipilimumab than with sunitinib but did not reach statistical significance (8.2 months versus 8.3 months; HR = 0.77, 95% CI 0.65–0.9). 18 A major caveat is that patients were accrued prior to approval of ICI for second-line treatment; subsequently, less than one-third of patients who received sunitinib and crossed-over to receive ICI as crossover were not allowed before approval.

also in 111,027 other papers